Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

valueinvestor1998 Aug. 5 at 9:35 PM

$BCTX The 16.6-month median OS is encouraging but highly uncertain: it came from a very small, selected Phase 2 subgroup, not a randomized comparison against physician’s-choice therapy. The broader formulation analysis showed HR 0.58 with a 95% CI of 0.20–1.40 so it was not statistically significant. Be careful with your investment and confidence here.

0 · Reply

Aye_Sir Aug. 5 at 9:21 PM

$BCTX hammertime

0 · Reply

ProfessorDman1 Aug. 5 at 8:28 PM

$BCTX this set up has all the ingredients for double digits runner (swing multi day )

0 · Reply

ProfessorDman1 Aug. 5 at 7:11 PM

$BCTX $INLF $JLHL $SPCX $YXT

1 · Reply

valueinvestor1998 Aug. 5 at 7:07 PM

$BCTX everyone please be careful. Too many clueless people pumping the stock on this board. Their previous results never showed statistical significance. KPTI just got wiped out because of a similar situation. If you want to invest here, keep in mind this is a lottery ticket. These guys have been an old major cancer, conferences, and many investors saw their work. There’s a reason they are trading so low.

3 · Reply

ProfessorDman1 Aug. 5 at 6:58 PM

$YXT from 3s to 25 💪🏾🤔 $BCTX 3s now with news and it will go soon .. 100%+ runner AH tonight or pre market tomorrow $INLF $SPCX $JLHL

0 · Reply

ZacksResearch Aug. 5 at 6:15 PM

$BCTX just cleared a major FDA hurdle — is this the next catalyst to watch? 🚀 ✅ The FDA issued a Study May Proceed letter for Bria-PROS+, clearing it for clinical evaluation in prostate cancer. 🧬 BriaCell says its personalized, off-the-shelf immunotherapy is designed to activate multiple components of the immune system, with preclinical data showing activation of T-cells, dendritic cells, and NK cells. Find more on BCTX here👉 https://www.zacks.com/stock/quote/BCTX?cid=sm-stocktwits-0-quote_overview-oc-39135&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39135

0 · Reply

MikeTechnician Aug. 5 at 5:21 PM

$BCTX adds another near-term catalyst: FDA clearance to initiate clinical evaluation of Bria-PROS+ in prostate cancer. News: https://bit.ly/4pX8Grz

0 · Reply

JediGreen Aug. 5 at 3:43 PM

$BCTX

0 · Reply

JediGreen Aug. 5 at 3:42 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2997) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html

0 · Reply

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 10 hours ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

2026-07-16T13:27:49.000Z - 20 days ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T11:40:48.000Z - 20 days ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

Thu, 16 Jul 2026 07:30:00 -0400 - 20 days ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

2026-07-15T13:32:56.000Z - 21 days ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T12:10:22.000Z - 21 days ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

Wed, 15 Jul 2026 07:30:00 -0400 - 21 days ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

2026-06-26T10:06:07.000Z - 5 weeks ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-25T13:25:58.000Z - 5 weeks ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 5 weeks ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 2 months ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 2 months ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 2 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 2 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 2 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 2 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 2 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 3 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 3 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 3 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 3 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 3 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 3 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 3 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 4 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 5 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 5 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 5 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 5 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 5 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 6 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T12:40:40.000Z - 6 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Jan 28, 2026, 7:30 AM EST - 6 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T12:41:04.000Z - 6 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Jan 27, 2026, 7:30 AM EST - 6 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 15, 2026, 4:05 PM EST - 7 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 7 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 7 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 7 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 7 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 7 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 8 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T12:41:29.000Z - 8 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

Dec 10, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 9, 2025, 7:30 AM EST - 8 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 2, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 9 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 10 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 10 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

valueinvestor1998 Aug. 5 at 9:35 PM

0 · Reply

Aye_Sir Aug. 5 at 9:21 PM

$BCTX hammertime

0 · Reply

ProfessorDman1 Aug. 5 at 8:28 PM

$BCTX this set up has all the ingredients for double digits runner (swing multi day )

0 · Reply

ProfessorDman1 Aug. 5 at 7:11 PM

$BCTX $INLF $JLHL $SPCX $YXT

1 · Reply

valueinvestor1998 Aug. 5 at 7:07 PM

3 · Reply

ProfessorDman1 Aug. 5 at 6:58 PM

$YXT from 3s to 25 💪🏾🤔 $BCTX 3s now with news and it will go soon .. 100%+ runner AH tonight or pre market tomorrow $INLF $SPCX $JLHL

0 · Reply

ZacksResearch Aug. 5 at 6:15 PM

0 · Reply

MikeTechnician Aug. 5 at 5:21 PM

$BCTX adds another near-term catalyst: FDA clearance to initiate clinical evaluation of Bria-PROS+ in prostate cancer. News: https://bit.ly/4pX8Grz

0 · Reply

JediGreen Aug. 5 at 3:43 PM

$BCTX

0 · Reply

JediGreen Aug. 5 at 3:42 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2997) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html

0 · Reply

OatesTheGoat Aug. 5 at 3:21 PM

$BCTX Over 3.6 watch for a move to $4

0 · Reply

MikeTechnician Aug. 5 at 2:35 PM

FDA says "Study May Proceed" for BriaCell's Bria-PROS+ prostate cancer program. Clinical testing is next. $BCTX Regulatory milestone ✅ News: https://bit.ly/4pX8Grz #Biotech #CancerImmunotherapy #ProstateCancer #HealthcareStocks

0 · Reply

Goodstockday Aug. 5 at 1:32 PM

$BCTX New company slogan: “BriaCell - We save both breasts and balls!”

0 · Reply

BCTX20bMC Aug. 5 at 1:26 PM

$BCTX The cry babies are broken records during the week…Dilution & RS is all they have…Then they fill out their signs & protest on weekends.

2 · Reply

Merlintrader Aug. 5 at 1:22 PM

$BCTX FDA clears the Bria-PROS+ IND, allowing a Phase 1/2a prostate-cancer study to begin https://www.merlintrader.com/briacell-therapeutics-stock-hub/

0 · Reply

MikeTechnician Aug. 5 at 1:16 PM

0 · Reply

BCTX20bMC Aug. 5 at 1:15 PM

$BCTX again…and again…and again….for the thick skulls with pea brains. They have enough $ to get them to the p3 readout. After the positive p3 news they will then prob raise more funds when the SP is 25+…Patience.

1 · Reply

ProfessorDman1 Aug. 5 at 12:46 PM

$BCTX news out and not sure why it’s not $5+ yet 🧐 I bought some herd mid 3s $AMIX went crazy yesterday $YXT going now $CISS still strong 💪🏾 $DBGI 💪🏾

0 · Reply

Kirubin Aug. 5 at 12:40 PM

$BCTX Where do you think the money will come from🥶🥶 ! offering machine. Expect plenty more coming your way!

1 · Reply

prismmarketview Aug. 5 at 12:37 PM

$BCTX FDA clearance is in for BriaCell’s Bria-PROS prostate cancer study, clearing the way for clinical evaluation of its cell-based immunotherapy candidate. https://prismmarketview.com/briacell-gets-fda-clearance-to-launch-bria-pros-study-in-prostate-cancer/

0 · Reply

BioTerror Aug. 5 at 12:16 PM

$BCTX when news drops on a low float and no ones paying attention. I'm loading... expecting a delayed reaction here ⏳💣

0 · Reply

KJolive Aug. 5 at 12:13 PM

$BCTX in for 5k shares

0 · Reply

Market Cap	29.23M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	208,647
Avg Vol	171,420
Day's Range	N/A - N/A
Shares Out	8.70M
Stochastic %K	19%
Beta	1.14
Analysts	Strong Buy
Price Target	$40.00